CommercialCoverageHigh impact
Lysis of Epidural Adhesions 7.01.73
Excellus BlueCross BlueShield·Pain Management, Neurosurgery, Orthopedics·Bone & Joints (Orthopedic)
Effective date
Oct 15, 2025
We identified it
Jul 16, 2026
Summary
Excellus BlueCross BlueShield has classified lysis of epidural adhesions (epidural adhesiolysis) as investigational, effective October 15, 2025. This means the procedure—performed via catheter-based or endoscopic techniques for back pain treatment—is not covered for reimbursement. Billing teams must deny or reject claims for this procedure and communicate non-coverage to providers.
Action Required
By October 15, 2025: (1) Billing team must update system edits to deny all claims for lysis of epidural adhesions/epidural adhesiolysis procedures submitted to Excellus BlueCross BlueShield plans; (2) Flag any pending claims for this procedure and contact providers to inform them of non-coverage status; (3) Update denial templates and correspondence to reference Policy 7.01.73 and cite investigational status; (4) Notify providers in pain management and interventional pain specialty of coverage denial through practice communication channels; (5) Ensure front-office staff are aware to obtain valid prior authorization denial letters before service dates when possible. Failure to implement these changes will result in claim denials by the payer and potential patient balance billing issues.